SynthesisPloS one2026
Diagnostic potential of total serum ghrelin in autoimmune gastritis: A systematic review and meta-analysis.
Synthesis in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAutoimmune gastritis (AIG) is a chronic inflammatory condition characterized by the destruction of gastric parietal cells. The invasive nature of diagnostic procedures and risk of confounding factors hinder the development of reliable diagnostic tools for AIG.
methodsWe conducted a systematic search of four databases. After assessing the study quality using the ROBINS-E tool, a meta-analysis was performed using a random-effects model. Meta-regression and sensitivity analyses were conducted to explore the sources of heterogeneity and impact of study bias.
resultsThe pooled mean difference in total serum ghrelin (pmol/L) between patients with AIG and healthy controls was -65.28 (95% CI: -178.54, 47.97). Subgroup analysis showed that the mean differences in serum ghrelin for mild, moderate, and severe atrophy were -78.85 (95% CI: -165.17, to 7.48), -91.97 (95% CI: -183.11, to -0.84), and -110.67 (95% CI: -204.77, to -16.56), respectively. The sensitivity analysis confirmed that the exclusion of studies with high-risk bias did not significantly alter the results. Meta-regression indicated that BMI contributed substantially to heterogeneity.
conclusionsAlthough total serum ghrelin levels were not significantly different between patients with AIG and healthy controls, significantly lower levels were observed in patients with moderate-to-severe gastric atrophy. Given the high heterogeneity and limitations of existing studies, the diagnostic utility of serum ghrelin in AIG warrants further investigation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.